Does the American Diabetes Association work for patients or companies?

Perceived ADA Misalignment and Conflicts of Interest

• Many commenters see the ADA as captured by corporate funders and not strongly aligned with patients’ interests.
• Sponsorships (e.g., from artificial sweetener companies) and branded recipes on ADA platforms are cited as emblematic conflicts.
• Some express disappointment the lawsuit settled before discovery, hoping investigations might expose internal decision-making.

Dietary Guidance, Carbs, and Diabetes Management

• Several diabetics and family members criticize ADA dietary recommendations as too carb-heavy and “worse than useless.”
• Strong pro–low-carb voices argue carbs drive hyperglycemia and insulin resistance, claiming low-carb or ketogenic diets can reverse type 2 and greatly aid glycemic control.
• Others counter that “carbs themselves” are not inherently harmful; the issue is refined, nutrient-poor foods and overall excess calories.
• There is disagreement over whether very low-carb diets are broadly healthy or sustainable long term.

Type 1 vs Type 2 and “Reversal”

• Broad agreement that type 1 diabetes requires exogenous insulin; diet and exercise can improve control but not eliminate this.
• Some push back on absolute language (“always no insulin”), citing residual endogenous insulin and variability.
• Multiple commenters reference research and personal experience suggesting many with type 2 can achieve remission via substantial weight loss or low-carb / very-low-calorie protocols (e.g., Newcastle Protocol, ketogenic programs).
• Skeptics question sustainability of severe calorie restriction and highlight risks like muscle loss and later weight regain.

Prediabetes and Diagnostic Thresholds

• One thread challenges whether “prediabetes” is a meaningful disease vs a risk label, noting the cutoff is near population medians.
• Others respond that elevated HbA1c is strongly associated with higher future diabetes and mortality risk; thresholds are somewhat arbitrary but clinically useful.
• Debate centers on semantics (“disease” vs “risk factor”) rather than on whether metabolic health is widely poor.

Artificial Sweeteners and Splenda Sponsorship

• A major subthread critiques ADA’s close relationship with Splenda, including sponsored newsletter content and many Splenda-based recipes.
• Cited studies associate non-sugar sweeteners with impaired glucose tolerance, obesity, cardiovascular disease, and higher type 2 risk, though causal direction is contested.
• Some argue artificial sweeteners are still valuable sugar substitutes and self-monitoring shows no acute glycemic impact; others stress microbiome and hormonal effects and WHO’s cautionary guidance.

Institutions, Incentives, and Expertise

• Commenters generalize from ADA to a broader “principal–agent” problem: many associations, unions, and bureaucracies drift toward self-preservation over mission.
• This fuels skepticism of “trust the experts / don’t do your own research” messaging; several argue laypeople can and should critically evaluate evidence, while others warn most people lack the skills and should rely on scientific consensus.
• Economic incentives are highlighted: pharma profits from chronic management; insurers and society bear costs of complications, suggesting misaligned motivations around prevention and cure.